Accessory wandering spleen: Report of a case of laparoscopic approach in an asymptomatic patient

A. Perin,R. Cola,F. Favretti

DOI: https://doi.org/10.1016/j.ijscr.2014.10.045

2014-10-18

International Journal of Surgery Case Reports

Abstract:

What problem does this paper attempt to address?

Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study

Yaroslav Winter,Raya Abou Dargham,Susana Patiño Tobón,Sergiu Groppa,Sven Fuest

DOI: https://doi.org/10.1007/s40263-024-01109-9

CNS Drugs

Abstract:Background and objectives: Cenobamate (CNB) is a new antiseizure medication (ASM) to treat drug-resistant, focal-onset seizures. Data on its use in early therapy lines are not yet available, and clinicians frequently consider CNB to be a later ASM drug choice. We investigated the efficacy and safety of CNB as an early adjunctive treatment in drug-resistant, focal-onset seizures. Methods: The study population were patients with drug-resistant, focal-onset seizures who were initiated with CNB after they did not respond to two or three lifetime ASMs, including all prior and concomitant ASMs. These patients were matched (1:2) by sex, age, and seizure frequency to controls who were initiated with any ASM other than CNB. All participants participated in the Mainz Epilepsy Registry. We evaluated the retention rate after 12 months of CNB and after each new adjunctive ASM in the control group. In addition, seizure freedom and the response rate (reduction of seizure frequency by ≥ 50% from baseline) after 12 months were estimated. Results: We included 231 patients aged 44.4 ± 15.8 years. Of these, 33.3% (n = 77) were on CNB, 19.0% (n = 44) on valproate (VPA), 17.3% (n = 40) on lacosamide (LCS), 16.4% (n = 38) on levetiracetam (LEV), and 13.9% (n = 32) on topiramate (TPM). The highest retention rate after 12 months since the beginning of the early adjunctive therapy was observed on CNB (92.0%), compared with LCS (80.0%), LEV (73.3%), VPA (68.2%), or TPM (62.5%) (p < 0.05). Seizure freedom and response rate were also the best on CNB (19.5% and 71.4%, respectively) compared with other ASMs (8.3% and 52.5%, respectively; p < 0.05). No significant differences in adverse events between CNB and other ASMs were observed. Conclusions: Our study provides evidence that CNB is an effective ASM with a good safety profile in the early therapy lines of drug-resistant, focal-onset seizures. This data should support medical decision making in the management of patients with refractory epilepsy. Clinical trial id: NCT05267405.
The cenobamate KORK study-A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam

Bernhard J Steinhoff,Dimitra Georgiou,Tassanai Intravooth

DOI: https://doi.org/10.1002/epi4.12992

Epilepsia Open

Abstract:Objective: In Europe, cenobamate has been approved for use as an adjunctive therapy in adult patients with epilepsy (PWE) with focal-onset seizures (FOS) who have not responded satisfactorily to treatment with at least two antiseizure medications (ASMs). Pivotal trials and real-world observational studies have demonstrated a high efficacy of cenobamate, even in very difficult-to-treat epilepsies. Our aim was to investigate the efficacy of add-on cenobamate in adult PWE who were prospectively monitored. We compared these results with those previously obtained for add-on lacosamide, perampanel, and brivaracetam therapy. Methods: Patients were enrolled from the CENKORK study, which is a prospective, non-interventional, open-label, monocenter cohort study of adult PWE experiencing FOS. The titration of cenobamate was performed according to the guidelines outlined in the summary of product characteristics. The primary outcome measure was the retention rate at 6 months and 1 year. In addition, we assessed seizure-free rates, the proportion of patients achieving at least a 50% seizure reduction, adverse events, and the reasons for treatment discontinuation. These outcome measures were compared with historical controls treated with adjunctive lacosamide, perampanel, or brivaracetam at our center. Results: Between June 2021 and 2022, 172 PWE with ongoing FOS were included. 22 cases were lost to follow-up, leaving 150 cases for the 1-year assessment. The retention rates at 6 months and 1 year were 88.7% and 80%, respectively. Seizure freedom was achieved in 14% of patients at both the 6-month and 1-year marks, while the ≥50% responder rates were 50% and 61%, respectively. The 6-month retention rate was significantly higher in cenobamate than in other ASMs (p < 0.001 for each comparator). Adverse events were significantly more common with perampanel (p < 0.001). Significance: Add-on cenobamate proved to be particularly efficacious compared to our experience with other recently introduced ASMs. Plain language summary: This observational study was carried out in 172 adult patients with difficult-to-treat epilepsy who were treated with adjunctive cenobamate. After 1 year, the data of 150 patients could be analyzed. Seizure freedom, in the preceding 3 months, was achieved in 14%. The rate of PWE continuing cenobamate was 80%. In our hands, cenobamate showed promising efficacy and tolerability even when compared to other recently introduced antiseizure medications.
The effectiveness of Cenobamate in patients previously treated with Vagus Nerve Stimulation for drug resistant epilepsy

Lara Hogeveen,Benjamin Legros,Alfred Meurs,Veerle De Herdt,Mathieu Sprengers,Stephanie Hoedl,Ann Mertens,Stefanie Gadeyne,Robrecht Raedt,Frank Dewaele,Jelle Vandersteene,Paul Boon,Kristl Vonck

DOI: https://doi.org/10.1101/2024.12.09.24318297

2024-12-10

Abstract:Background: Vagus Nerve Stimulation (VNS) is an efficacious neuromodulatory treatment for patients with drug resistant epilepsy (DRE). In many VNS treated patients, seizures are not fully controlled. These patients often represent a highly refractory group in whom novel anti-seizure medication (ASM) may be tried. This study evaluates the effectiveness of Cenobamate (CNB) in patients previously treated with VNS. Methods: The medication history of all patients treated with VNS at Ghent University Hospital and HUB-Hopital Erasme Brussels between 1995 and 2024 was reviewed. In patients who received an add-on treatment with CNB after at least 12 months of VNS therapy, mean monthly seizure frequency before VNS, after VNS, and after CNB was assessed. Results: 54/620 patients treated with VNS between March 1995 and November 2023 were treated with CNB after a median VNS treatment time of 9 years. With VNS, 13/52 (25%) had a seizure frequency reduction of ≥50%. Side-effects were mild and stimulation-related. After add-on of CNB (median daily dosage of 200mg) for a median follow-up of 10 months, 24/54 (44.4%) became responders. Of these patients, 6 (11.1% from total cohort) reported seizure freedom for a median duration of 26 weeks. Almost half (46.2%) of the VNS non-responders became CNB responder. The median number of concomitant ASM was 3. In 20/54 (37%), the number of ASM was reduced. 7/54 (13%) stopped CNB because of side-effects. Fatigue was the most prevalent side effect in 23/54 patients (42.6%). Conclusion: In DRE patients treated with VNS therapy who could benefit from further improvement in seizure control, add-on treatment with CNB is useful. This most recently marketed ASM leads to a significant improvement in seizure frequency in more than 40% of the patients.
Treatment simplification to optimize cenobamate effectiveness and tolerability: A real-world retrospective study in Spain

Juan Jesús Rodríguez-Uranga,Juan María Sánchez-Caro,Roshan Hariramani Ramchandani

DOI: https://doi.org/10.1002/epi4.12959

Epilepsia Open

Abstract:Objective: This study aimed to explore the impact of co-antiseizure medication (co-ASM) optimization on the effectiveness and tolerability of adjunctive cenobamate (CNB) in patients with drug-resistant epilepsy in a real-world setting. Methods: This unicentric, retrospective, observational study included adults with focal-onset seizures who had received ≥2 previous ASMs. The main effectiveness endpoints included responder rates and seizure frequency reduction at 3, 6, and 12-month visits. The number of co-ASMs and defined daily dose (DDD) were analyzed at every visit. Safety endpoints included adverse drug reactions (ADRs). Results: Thirty-four patients with a median epilepsy duration of 22 years and a median of 15.5 seizures/month were analyzed. The median number of prior ASMs was 12, and the mean number of co-ASMs was 2.9 (SD 1). There was a reduction in seizure frequency/month from baseline to the last visit (p < 0.0001). Between baseline and the end of the study, the mean number of co-ASMs in the per-protocol (PP) population was reduced from 2.9 to 1.6 (p < 0.0001), and DDD was reduced from 3.6 to 1.4 (p < 0.0001). Sodium channel blockers (carbamazepine and lacosamide) and GABAergic drugs (clobazam) were the agents with the most significant reductions in DDD after 12 months. The percentage of patients in the PP population with ≥3 co-ASMs was reduced from 61.8% at baseline to 14.3% at 12 months; 1 patient was receiving CNB as monotherapy at the last visit. At the last visit, 85.7% of the PP population were ≥50% responders, and 33.3% were seizure-free. The percentage of patients with ADRs in the PP population was 71.9% at 3 months and 52.3% at 12 months. Significance: Following rational polytherapy, optimization of co-ASM management during CNB treatment allowed high seizure freedom rates despite meaningful reductions in co-medication, while also achieving both good tolerability and patient satisfaction scores in a highly drug-resistant population. Plain language summary: Many patients with epilepsy still have seizures, even after being treated with several different epilepsy drugs. In this study of 34 patients from a Spanish clinic, we show that the epilepsy drug cenobamate can reduce the number of seizures in these patients, even after many other epilepsy drugs have failed. We also show that patients treated with cenobamate can reduce the dose or even stop taking certain other epilepsy drugs. This allows them to simplify their treatment and reduce adverse effects while still keeping control of their epilepsy.
Adjunctive cenobamate in people with focal onset seizures: Insights from the Italian Expanded Access Program

Roberta Roberti,Giovanni Assenza,Francesca Bisulli,Giovanni Boero,Laura Canafoglia,Valentina Chiesa,Carlo Di Bonaventura,Giancarlo Di Gennaro,Maurizio Elia,Edoardo Ferlazzo,Alfonso Giordano,Angela La Neve,Claudio Liguori,Stefano Meletti,Francesca Felicia Operto,Nicola Pietrafusa,Monica Puligheddu,Patrizia Pulitano,Eleonora Rosati,Ilaria Sammarra,Elena Tartara,Giampaolo Vatti,Flavio Villani,CNB EAP Italy Study Group,Emilio Russo,Simona Lattanzi,Sabina Bartalini,Costanza Calabrese,Emanuele Cerulli Irelli,Roberta Coa,Giuseppe Didato,Giovanni Falcicchio,Mariana Fernandes,Francesco Fortunato,Renato Frangiosa,Edoardo Fronzoni,Domenico Lomonaco,Roberto Matrullo,Elisa Micalizzi,Alessandra Morano,Lorenzo Muccioli,Chiara Panzini,Angelo Pascarella,Emilia Ricci,Licia Salimbene,Mario Tombini,Anna Elisabetta Vaudano

DOI: https://doi.org/10.1111/epi.18091

IF: 6.74

2024-08-14

Epilepsia

Abstract:Objective: This study was undertaken to assess the effectiveness/tolerability of adjunctive cenobamate, variations in the load of concomitant antiseizure medications (ASMs) and predictors of clinical response in people with focal epilepsy. Methods: This was a retrospective study at 21 centers participating in the Italian Expanded Access Program. Effectiveness outcomes included retention and responder rates (≥50% and 100% reduction in baseline seizure frequency). Tolerability/safety outcomes included the rate of treatment discontinuation due to adverse events (AEs) and their incidence. Total drug load was quantified as the number of concomitant ASMs and total defined daily dose (DDD). Concomitant ASMs were also classified according to their mechanism of action and pharmacokinetic interactions to perform explorative subgroup analyses. Results: A total of 236 subjects with a median age of 38 (Q1-Q3 = 27-49) years were included. At 12 months, cenobamate retention rate was 78.8% and responders were 57.5%. The seizure freedom rates during the preceding 3 months were 9.8%, 12.2%, 16.3%, and 14.0% at 3, 6, 9, and 12 months. A higher percentage of responders was observed among subjects treated with clobazam, although the difference was not statistically significant. A total of 223 AEs were recorded in 133 of 236 participants, leading to cenobamate discontinuation in 8.5% cases. At 12 months, a reduction of one or two concomitant ASMs occurred in 42.6% and 4.3% of the subjects. The median total DDD of all concomitant ASMs decreased from 3.34 (Q1-Q3 = 2.50-4.47) at baseline to 2.50 (Q1-Q3 = 1.67-3.50) at 12 months (p < .001, median percentage reduction = 22.2%). The highest rates of cotreatment withdrawal and reductions in the DDD were observed for sodium channel blockers and γ-aminobutyric acidergic modulators (above all for those linked to pharmacokinetic interactions), and perampanel. Significance: Adjunctive cenobamate was associated with a reduction in seizure frequency and in the burden of concomitant ASMs in adults with difficult-to-treat focal epilepsy. The type of ASM associated did not influence effectiveness except for a favorable trend with clobazam.
Effect of Rossby and Alfvén Waves on the Dynamics of the Tachocline

N. Leprovost,Eun-jin Kim

DOI: https://doi.org/10.1086/509713

2006-07-24

Abstract:To understand magnetic diffusion, momentum transport, and mixing in the interior of the Sun, we consider an idealized model of the tachocline, namely, magnetohydrodynamic (MHD) turbulence on a β-plane subject to a large-scale shear (provided by the latitudinal differential rotation). This model enables us to self-consistently derive the influence of shear, Rossby, and Alfvén waves on the transport properties of turbulence. In the strong magnetic field regime, we find that the turbulent viscosity and diffusivity are reduced by magnetic fields only, as in the two-dimensional MHD case (without Rossby waves). In the weak magnetic field regime, we find a crossover scale (LR) from a Alfvén-dominated regime (on small scales) to a Rossby-dominated regime (on large scales). For parameter values typical of the tachocline, LR is larger than the solar radius so that Rossby waves are unlikely to play an important role in the transport of magnetic field and angular momentum. This is mainly due to the enhancement of magnetic back-reaction by shearing, which efficiently generates small scales, and thus strong currents.
A VAMS-based LC-MS/MS method for precise cenobamate quantification in epilepsy (patients)

Federica Pigliasco,Alessia Cafaro,Sebastiano Barco,Margherita Biondi,Manuela Stella,Francesca Mattioli,Antonella Riva,Ugo de Grazia,Linda Molteni,Elisa Micalizzi,Flavio Villani,Pasquale Striano,Roberto Bandettini,Giuliana Cangemi

DOI: https://doi.org/10.1002/epi4.12927

2024-09-19

Epilepsia Open

Abstract:Objective: Cenobamate (CNB), a recently approved antiseizure medication by the European Medicines Agency (EMA), serves as an adjunctive therapy for focal-onset seizures in adult patients unresponsive to at least two other treatments. Administered in polytherapy, CNB can potentially interact with co-administered drugs in epilepsy patients, necessitating dose adjustments and the need for effective therapeutic drug monitoring (TDM). Methods: In this study, we introduce a novel LC-MS/MS method for precise CNB quantification using Volumetric Absorptive Microsampling (VAMS), following validation according to ICH guidelines M10. VAMS samples are efficiently extracted with 200 μL of methanol, with chromatographic separation achieved using an Acquity UPLC HSS PFP column. The method's efficacy was confirmed through its application to real samples from adult CNB-treated patients. Results: Our results demonstrate that the method exhibits linearity within the range of 0.05-30 mg/L, with intra- and inter-run precision ranging from 1% to 8% and accuracy from 1% to 10% based on 30 μL of sample. Furthermore, CNB stability in VAMS is confirmed for up to 15 days at 25°C and -20°C. Importantly, no significant difference was observed between CNB concentrations in VAMS samples and those in plasma obtained from venous blood. Significance: This VAMS-based LC-MS/MS method presents a robust alternative for TDM in CNB-treated patients. Future investigations should explore CNB concentrations in capillary blood and assess their correlation with plasma levels to further enhance its clinical utility. Plain language summary: Cenobamate is an antiepileptic drug and used for treatment of focal-onset seizures in adult patients (≥18 age). TDM can prevent drug interactions and minimize drug toxicity. The aim of this work is to evaluate volumetric absorptive microsampling (VAMS) from capillary blood as an alternative strategy for TDM in patients treated with the newly antiepileptic drug. Our method is suitable for TDM, and this study suggests that VAMS allows monitoring of cenobamate concentration and can offer valuable support for personalized therapy in refractory epilepsy.
Finding homes without smoke detectors: one step in planning burn prevention programs.

R. McKnight,T. Struttmann,J. Mays

DOI: https://doi.org/10.1097/00004630-199509000-00016

1995-09-01

Abstract:Residential fires are the leading cause of burn-related deaths in the United States. Smoke detectors could save many of these lives. A 1993 telephone survey of 661 Kentucky households included questions on residential smoke detectors. Statewide, 16.4% of households did not possess a functioning smoke detector; however, in nonmetropolitan Appalachian counties, 30.5% of households lacked detectors. Characteristics associated with lack of a functioning smoke detector, as determined by multivariate logistic regression, were as follows: living in a nonapartment dwelling (odds ratio [OR] = 4.14, 95% confidence interval [CI] = 1.42 to 12.01); having an annual household income of $20,000 or less (OR = 2.34, CI = 1.49 to 3.68); being unmarried (OR = 1.73, CI = 1.12 to 2.69); living alone (OR = 1.69, CI = 1.02 to 2.80); and living in a nonmetropolitan county (OR = 1.68, CI = 1.05 to 2.69). Knowledge of these population-based characteristics can assist planners of burn prevention programs to target at-risk populations.
Development and Validation of a UHPLC–MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples

Bruno Charlier,Albino Coglianese,Francesca Felicia Operto,Giangennaro Coppola,Ugo de Grazia,Pierantonio Menna,Amelia Filippelli,Fabrizio Dal Piaz,Viviana Izzo

DOI: https://doi.org/10.3390/molecules27217325

IF: 4.6

2022-10-29

Molecules

Abstract:Cenobamate (CNB) is the newest antiseizure medication (ASM) approved by the FDA in 2019 to reduce uncontrolled partial-onset seizures in adult patients. Marketed as Xcopri in the USA or Ontozry in the EU (tablets), its mechanism of action has not been fully understood yet; however, it is known that it inhibits voltage-gated sodium channels and positively modulates the aminobutyric acid (GABA) ion channel. CNB shows 88% of oral bioavailability and is responsible for modifying the plasma concentrations of other co-administered ASMs, such as lamotrigine, carbamazepine, phenytoin, phenobarbital and the active metabolite of clobazam. It also interferes with CYP2B6 and CYP3A substrates. Nowadays, few methods are reported in the literature to quantify CNB in human plasma. The aim of this study was to develop and validate, according to the most recent guidelines, an analytical method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC–MS/MS) to evaluate CNB dosage in plasma samples. Furthermore, we provided a preliminary clinical application of our methodology by evaluating the pharmacokinetic parameters of CNB in two non-adult patients. Plasma levels were monitored for two months. Preliminary data showed a linear increase in plasma CNB concentrations, in both patients, in agreement with the increase in CNB dosage. A seizure-free state was reported for both patients at the dose of 150 mg per day.

chemistry, multidisciplinary,biochemistry & molecular biology
Cenobamate add-on therapy for drug-resistant focal epilepsy

Francesco Brigo,Simona Lattanzi

DOI: https://doi.org/10.1002/14651858.CD014941.pub2

2024-08-01

Abstract:Background: Although most people with epilepsy achieve complete seizure cessation, approximately one-third of those with the condition continue experiencing seizures despite the use of antiseizure medications (ASMs) given as monotherapy or polytherapy. In this review, we summarised the evidence from randomised controlled trials (RCTs) about cenobamate as an add-on treatment for focal epilepsy uncontrolled by one or more concomitant ASMs. Objectives: To assess the efficacy and tolerability of add-on oral cenobamate for the treatment of drug-resistant focal-onset seizures, defined as seizures persisting despite treatment with one or more ASMs. Search methods: We searched the Cochrane Register of Studies (CRS Web) and MEDLINE Ovid (September 2022). In addition, we contacted the manufacturer of cenobamate and experts in the field to enquire after any ongoing or unpublished studies. Selection criteria: RCTs comparing add-on cenobamate to placebo or another ASM in people with focal epilepsy uncontrolled by one or more concomitant ASMs. Data collection and analysis: Two review authors independently selected trials for inclusion, extracted data, performed risk of bias assessment, and assessed the certainty of the evidence using the GRADE approach. Our primary outcomes were at least a 50% reduction in total seizure frequency, seizure freedom, and the occurrence of adverse events. We used an intention-to-treat approach for our primary analyses. For each outcome we estimated summary risk ratios (RRs) with their 95% confidence intervals (CIs). We summarised the estimates of effects and certainty of the evidence for each outcome in a summary of findings table. Main results: We included two studies (659 adult participants, 442 allocated to cenobamate and 217 to placebo). The overall RR for at least a 50% reduction in seizure frequency for add-on cenobamate at any dose compared to placebo was 2.17 (52% versus 24%, 95% CI 1.66 to 2.84; 2 studies, 605 participants; moderate-certainty evidence). The RR for seizure freedom for add-on cenobamate at any dose compared to placebo was 4.45 (16% versus 5%, 95% CI 2.25 to 8.78; 2 studies, 605 participants; moderate-certainty evidence). The RR for the occurrence of adverse events for add-on cenobamate at any dose compared to placebo was 1.14 (77% versus 67%, 95% CI 1.02 to 1.27; 2 studies, 659 participants; moderate-certainty evidence). We judged the two included RCTs as at low or unclear risk of bias. Both studies were sponsored by the drug company that produces cenobamate. Authors' conclusions: Add-on cenobamate is probably better than placebo in reducing the frequency of seizures by at least 50% and in achieving seizure freedom in adults with focal epilepsy uncontrolled by one or more concomitant ASMs (moderate level of certainty). Its use is probably associated with an increased risk of adverse events (moderate level of certainty). Further prospective, controlled trials are required to evaluate the efficacy and tolerability of add-on cenobamate compared to other ASMs. The efficacy and tolerability of cenobamate as adjunctive treatment for focal epilepsy in children should be further investigated. Finally, the long-term efficacy and tolerability of add-on cenobamate treatment in people with other epilepsy types (e.g. generalised epilepsy) or specific epilepsy syndromes, as well as its use as monotherapy, require additional study.
Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations

Bernhard J. Steinhoff,Elinor Ben-Menachem,Pavel Klein,Jukka Peltola,Bettina Schmitz,Rhys H. Thomas,Vicente Villanueva

DOI: https://doi.org/10.1177/17562864241256733

2024-01-01

Therapeutic Advances in Neurological Disorders

Abstract:The goal of epilepsy treatment is seizure freedom, typically with antiseizure medication (ASM). If patients fail to attain seizure control despite two trials of appropriately chosen ASMs at adequate doses, they are classified as having drug-resistant epilepsy (DRE). Adverse events (AEs) commonly occur in people with DRE because they are typically on ⩾2 ASMs, increasing the potential for drug–drug interactions. Early emerging AEs may impact adherence, decrease quality of life, and delay achieving optimal treatment dosages. Cenobamate is an oral ASM with a long half-life which has proven to be highly effective in clinical trials. An international Delphi panel of expert epileptologists experienced in the clinical use of cenobamate and other ASMs was convened to develop consensus best practices for managing patients during and after cenobamate titration, with consideration for its known pharmacokinetic and pharmacodynamic interactions, to allow patients to reach the most appropriate cenobamate dose while limiting tolerability issues. The modified Delphi process included one open-ended questionnaire and one virtual face-to-face meeting. Participants agreed that cenobamate can be prescribed for most patients experiencing focal-onset seizures. Patients initiating cenobamate therapy should have access to healthcare professionals as needed and their treatment response should be evaluated at the 100-mg dose. Patients with intellectual disabilities may need additional support to navigate the titration period. Proactive down-titration or withdrawal of sodium channel blockers (SCBs) is recommended when concomitant ASM regimens include ⩾2 SCBs. When applicable, maintaining a concomitant clobazam dose at ~5–10 mg may be beneficial. Patients taking oral contraceptives, newer oral anticoagulants, or HIV antiretroviral medications should be monitored for potential interactions. Because clinical evidence informing treatment decisions is limited, guidance regarding dose adjustments of non-ASM drugs was not developed beyond specific recommendations presented in the Summary of Product Characteristics.

clinical neurology
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry

Linda Molteni,Bruno Charlier,Albino Coglianese,Viviana Izzo,Giovanni Assenza,Pierantonio Menna,Ugo de Grazia,Annachiara D’Urso,Annachiara D'Urso

DOI: https://doi.org/10.3390/molecules29040884

IF: 4.6

2024-02-18

Molecules

Abstract:Cenobamate (CNB) is a new anti-seizure medication (ASM) recently introduced in clinical practice after approval by the FDA and EMA for the add-on treatment of focal onset seizures in adult patients. Although its mechanism of action has not been fully understood, CNB showed promising clinical efficacy in patients treated with concomitant ASMs. The accessibility of CNB could pave a way for the treatment of refractory or drug-resistant epilepsies, which still affect at least one-third of the patients under pharmacological treatment. In this context, therapeutic drug monitoring (TDM) offers a massive opportunity for better management of epileptic patients, especially those undergoing combined therapy. Here, we describe the first fully validated ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC–MS/MS) method for the quantification of CNB and concomitant ASMs in human plasma, with samples extracted either manually or by means of a liquid handler. Our method was validated according to the most recent ICH International Guideline M10 for Bioanalytical Method Validation and Study Sample Analysis. The method proved to be selective for CNB and displayed a linear range from 0.8 to 80 mg/L; no matrix effect was found (98.2 ± 4.1%), while intra-day and inter-day accuracy and precision were within the acceptance range. Also, CNB short- and long-term stability in plasma under different conditions was assessed. Leftover human plasma samples were employed as study samples for method validation. Our method proved to be highly sensitive and selective to quantify CNB and concomitant ASMs in human plasma; therefore, this method can be employed for a routinely TDM-based approach to support physicians in the management of an epileptic patient.

chemistry, multidisciplinary,biochemistry & molecular biology
Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy

Cathrine Elisabeth Gjerulfsen,Madeleine Oudin,Francesca Furia,Sopio Gverdtsiteli,Cecilie Johannessen Landmark,Marina Trivisano,Angel Aledo-Serrano,Ricardo Morcos,Roberto Previtali,Pierangelo Veggiotti,Emilia Ricci,Guido Rubboli,Elena Gardella,Rikke Moller

DOI: https://doi.org/10.1101/2024.10.17.24312949

2024-10-21

Abstract:Objectives: Developmental and epileptic encephalopathies (DEEs) caused by pathogenic variants in SCN8A are associated with difficult-to-treat and early-onset seizures, developmental delay/intellectual disability, impaired quality of life, and increased risk of early mortality. Commonly used antiseizure medications (ASMs) for SCN8A-related disorders, caused by gain-of-function variants, are sodium channel blockers. The use of such ASMs is often not enough to gain satisfactory seizure control. In this retrospective study, the effect of cenobamate was assessed in patients with SCN8A-DEE. Methods: Across multiple centers and through a collaboration with the patient advocacy organization International SCN8A Alliance, patients with SCN8A-DEE treated with cenobamate for at least 3 months were identified. Data were obtained once from patients' caregivers or treating physicians through a RedCap survey. The functional effects of the included patients' SCN8A variants were determined by functional tests published in the literature or functionally classified by prediction tools. Results: Twelve patients (2-25 years, 8 females) with presumed gain-of-function SCN8A variants were treated with cenobamate for a mean period of 8.6 months (range 3-27 months). Countable motor seizures were reduced in 12/12 (100%) patients. Seven experienced a seizure reduction above 75% of which two patients achieved seizure freedom. A 25-50% and 50-75% decrease was observed in three and two patients, respectively. An increase in seizure-free days/patient was also reported. Rescue medication was decreased in 83% of patients, and non-seizure-related improvements (increased alertness, better sleep, improved muscle tone) were observed in 58%. Adverse effects were reported by 33%; half resolved spontaneously or by the reduction of concomitant ASMs. Significance: Our data suggest, that cenobamate is a promising and safe treatment for SCN8A-DEE, even during early infancy. As a possible precision approach to treatment, cenobamate effectively reduced seizure burden and ameliorated non-seizure-related symptoms. Similar results may be achieved in cohorts of patients with gain-of-function variants encoding other sodium channels
[Brain necrosis following intraoperative radiation therapy or interstitial brachytherapy].

O. Nakamura,M. Matsutani,H. Tanaka,K. Ueki,T. Nagashima,Y. Tanaka

1988-12-01

Abstract:We have experienced 8 cases of radiation necrosis which occurred following radiation therapy of malignant brain tumors. In all 8 cases, necrosis developed in the brain tissue adjacent to the tumor after intraoperative radiation or interstitial radiation therapy. Considering that the extent of necrosis usually coincides with the extent of the radiation therapy, this type of necrosis is thought to be the expected result of radiation therapy. A differential diagnosis between radiation necrosis and the recurrence of a brain tumor has been thought to be difficult to achieve. Yet with the use of a dynamic CT or an Xe-enhanced CT, differential diagnosis between these two lesions was clearly accomplished.
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability

Roberta Roberti,Carmen De Caro,Luigi Francesco Iannone,Gaetano Zaccara,Simona Lattanzi,Emilio Russo

DOI: https://doi.org/10.1007/s40263-021-00819-8

2021-05-16

CNS Drugs

Abstract:Cenobamate is one of the latest antiseizure medications (ASMs) developed for the treatment of focal onset seizures in adult patients. The recommended starting dose is 12.5 mg/day, titrated gradually to the target daily dose of 200 mg, which may be increased to a maximum of 400 mg/day based on clinical response. Although the high rate of seizure freedom observed in randomized, placebo-controlled clinical trials has resulted in exciting expectations, further clinical studies are needed to better define its clinical profile. Cenobamate is characterized by a peculiar pharmacology regarding both pharmacodynamics and pharmacokinetics. The mechanism of action has only partly been described, with the drug acting on voltage-gated sodium channels through a pronounced action on persistent rather than transient currents. Cenobamate also acts as a positive allosteric modulator of GABA<sub>A</sub> receptors independently from the benzodiazepine binding site. The bioavailability of cenobamate is not influenced by other drugs, except phenytoin; it can inhibit cytochrome P450 (CYP) 2C19 and induce CYP3A4 and 2B6, and hence can potentially interact with many drugs (e.g. dose adjustments may be required for lamotrigine, carbamazepine and clobazam). The pharmacokinetics of cenobamate are not linear and dosage increases imply a disproportional increase in plasma levels, particularly at doses higher than 300 mg. The most common and dose-related adverse effects associated with cenobamate include central nervous system-related symptoms, mainly somnolence, dizziness, diplopia, and disturbances in gait and coordination. A somewhat higher incidence of adverse events has been observed in patients concomitantly treated with sodium channel blockers. The most relevant safety issues are currently represented by the risk of severe skin reactions (apparently avoidable by a slow titration) and QT shortening (the drug is contraindicated in patients with familial short QT syndrome or taking QT-shortening drugs). Overall, cenobamate is a promising ASM with an intriguing and not fully understood mechanism of action; pharmacokinetic issues need to be considered in clinical practice.

pharmacology & pharmacy,psychiatry,clinical neurology
Severe memory decline along with unaffected executive functions under 400 mg/day of cenobamate leading to a collapse in school performance

Juri-Alexander Witt,Susanna Moskau-Hartmann,Karmele Olaciregui Dague,Rainer Surges,Christoph Helmstaedter

DOI: https://doi.org/10.1080/13554794.2024.2366472

2024-06-15

Neurocase

Abstract:Cenobamate (CNB) is one of the newer antiseizure medications for the treatment of focal-onset seizures. The cognitive profile of CNB is not yet known in detail. Here we present the case of an 18-year-old male high school student with epilepsy who received adjunctive CNB. Under 400 mg/d of CNB in combination with lamotrigine, a neuropsychological reassessment revealed a severe deterioration of the formerly normal episodic memory functions, while executive functions remained unaffected. The de novo memory deficit had already led to a collapse in school performance and he unexpectedly failed to obtain the general qualification for university entrance. Given the beneficial effect of CNB on seizure control, a dose reduction of CNB to 200 mg/d and introduction of valproic acid was performed. This led to a full recovery of objective memory performance. To our knowledge this is the very first report of a dose-dependent, selective and severe decline in episodic memory performance under CNB, potentially impeding academic achievement. The findings call for a cognitive monitoring of CNB which also addresses episodic memory in addition to executive functions. Systematic studies on episodic memory upon CNB treatment would help to appreciate the scope of this apparently reversible adverse effect.

psychiatry,clinical neurology,psychology
Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients: Post Hoc Analysis of a Phase III, Multicenter, Open-Label Study

Rebecca O’Dwyer,Sean Stern,Clarence T. Wade,Anuradha Guggilam,William E. Rosenfeld

DOI: https://doi.org/10.1007/s40266-024-01102-3

2024-03-07

Drugs & Aging

Abstract:Cenobamate is an antiseizure medication (ASM) approved in the US and Europe for the treatment of uncontrolled focal seizures.

pharmacology & pharmacy,geriatrics & gerontology,gerontology
Effectiveness and Safety of Adjunctive Cenobamate in People with Focal-Onset Epilepsy: Evidence from the First Interim Analysis of the BLESS Study

Lattanzi, Simona,Di Bonaventura, Carlo,Bonanni, Paolo,Gambardella, Antonio,Tartara, Elena,Assenza, Giovanni,Procaccini, Michela,Falsetto, Nathalie,Villano, Valentina,Camattari, Gabriele,Ori, Alessandra,Di Gennaro, Giancarlo

DOI: https://doi.org/10.1007/s40120-024-00634-5

2024-06-09

Neurology and Therapy

Abstract:Despite new anti-seizure medications (ASMs) being introduced into clinical practice, about one-third of people with epilepsy do not reach seizure control. Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. In randomized controlled trials, adjunctive cenobamate reduced the frequency of focal seizures in people with uncontrolled epilepsy. Studies performed in real-world settings are useful to complement this evidence and better characterize the drug profile.

clinical neurology
Correlation with Efficacy and Tolerability?

Bernhard J. Steinhoff,Dimitra Georgiou,Daniel Dietmann,Tassanai Intravooth

DOI: https://doi.org/10.3390/jcm13102757

IF: 3.9

2024-05-08

Journal of Clinical Medicine

Abstract:Objective: Cenobamate is approved by the European Medicine Agency for the treatment of adult patients with epilepsy (PWEs) with ongoing focal-onset seizures despite appropriate treatment with at least two established antiseizure medications. Pivotal trials and post-marketing real-world observational studies suggest high efficacy with unusually high seizure-free rates. The authors sought to investigate the plasma levels of cenobamate under steady-state conditions in seizure-free versus non-responding PWEs, and in PWEs who experienced adverse events versus those who did not. Methods: Blood samples were collected from adult PWEs who were treated with adjunct cenobamate under steady-state conditions. Daily doses, concomitant medications, efficacy, and tolerability were assessed. The plasma cenobamate levels of seizure-free versus non-responding PWEs and between PWEs with and those without clinical adverse events were compared. Results: Samples from 101 PWEs were included. Thirty-six PWEs were seizure-free and 65 were non-responders. In 31 PWEs, adverse events were apparent, whereas in the remaining 70, no tolerability issues were reported. A linear correlation was found between the daily doses (range: 100 mg–400 mg) and the plasma levels (3.8 mg/L–54.6 mg/L). Neither the daily doses nor the plasma levels differed significantly between the investigated subgroups. The main reason for this result was that the individual therapeutic ranges varied widely: seizure freedom and adverse effects were observed alongside low doses and plasma levels in some PWEs. Conversely, there were examples of PWEs who did not respond or who reported no tolerability issues at high doses or plasma levels. Conclusions: To evaluate the individual therapeutic range and to better understand the influence of other drugs in cases where concomitant medications are used, the therapeutic drug monitoring of cenobamate may be useful. A general therapeutic range cannot be defined.

medicine, general & internal
Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: Post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study

Sami Aboumatar,Louis Ferrari,Sean Stern,Clarence T Wade,Mindl Weingarten,Gregory S Connor,William E Rosenfeld,Clarence T. Wade,Gregory S. Connor,William E. Rosenfeld

DOI: https://doi.org/10.1016/j.eplepsyres.2024.107306

IF: 2.991

2024-02-01

Epilepsy Research

Abstract:OBJECTIVE: Many patients with epilepsy require polytherapy, which increases their antiseizure medication (ASM) drug load, a measure that considers the doses of all ASMs a patient is taking. Changes in concomitant ASM drug load after adding cenobamate were evaluated post-hoc in a subset of the open-label, phase 3 study.METHODS: Patients 18-70 years old with uncontrolled focal seizures taking 1-3 ASMs were enrolled. Total concomitant ASM drug load (not including cenobamate) was calculated by dividing the patient's prescribed dose for each ASM by its defined daily dose, per the World Health Organization, then summing the ratios. Changes in concomitant ASM drug load were measured from baseline in 3-month intervals up to 24 months by both total and class-specific ASM drug load. Subgroups of interest included: older adults (65-70 years), prior epilepsy-related surgery vs none, and baseline seizure frequency < 3 vs ≥ 3 seizures/28 days.RESULTS: Data from 240 patients were available (mean age 41.8 years, mean baseline drug load 3.57). Following cenobamate initiation, the mean concomitant ASM drug load was reduced by 29.4 % at Month 12 % and 31.8 % at Month 24. Reductions occurred in all assessed ASM drug classes, with the largest reduction in benzodiazepines (55.2 % at Month 24). Each assessed subgroup exceeded a 30 % reduction in concomitant ASM drug load at Month 24. Over 24 months, maintenance of ≥ 50 % response occurred in 89.3 %, 86.4 %, and 90.6 % of patients with low (-0.25 to <0), moderate (-0.59 to -0.25), or high (-3.3 to -0.59) numerical reductions in concomitant ASM drug load from baseline, respectively, compared with 86.0 % in patients with no change in drug load; maintenance of 100 % response occurred in 80.7 %, 84.3 %, and 70.0 % of patients with low, moderate, or high numerical reductions in concomitant ASM drug load, compared with 82.0 % in patients with no change.CONCLUSIONS: Adding cenobamate led to reduced mean concomitant ASM drug loads during 1 and 2 years of treatment. Reductions occurred regardless of ASM drug class, patient age, or epilepsy disease characteristics and did not impact maintenance of response rates.

clinical neurology

Accessory wandering spleen: Report of a case of laparoscopic approach in an asymptomatic patient

Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study

The cenobamate KORK study-A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam

The effectiveness of Cenobamate in patients previously treated with Vagus Nerve Stimulation for drug resistant epilepsy

Treatment simplification to optimize cenobamate effectiveness and tolerability: A real-world retrospective study in Spain

Adjunctive cenobamate in people with focal onset seizures: Insights from the Italian Expanded Access Program

Effect of Rossby and Alfvén Waves on the Dynamics of the Tachocline

A VAMS-based LC-MS/MS method for precise cenobamate quantification in epilepsy (patients)

Finding homes without smoke detectors: one step in planning burn prevention programs.

Development and Validation of a UHPLC–MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples

Cenobamate add-on therapy for drug-resistant focal epilepsy

Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations

Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry

Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy

[Brain necrosis following intraoperative radiation therapy or interstitial brachytherapy].

Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability

Severe memory decline along with unaffected executive functions under 400 mg/day of cenobamate leading to a collapse in school performance

Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients: Post Hoc Analysis of a Phase III, Multicenter, Open-Label Study

Effectiveness and Safety of Adjunctive Cenobamate in People with Focal-Onset Epilepsy: Evidence from the First Interim Analysis of the BLESS Study

Correlation with Efficacy and Tolerability?

Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: Post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study